As indicated by immunohistochemical studies, when mice were treated with endostatin delivered by our engineered Salmonella, the expression level of CD34 inside tumor tissue was significantly decreased compared to PBS or Salmonella treatment groups, thus confirming the in vivo anti-angiogenic activity of endostatin. Here, CD34 is linked to neoplasm.